TITLE

Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon α mono and combination therapy regimens

AUTHOR(S)
Schmid, M.; Kreil, A.; Jessner, W.; Homoncik, M.; Datz, C.; Gangi, A.; Ferenci, P.; Peck-Radosavljevic, M.
PUB. DATE
July 2005
SOURCE
Gut;Jul2005, Vol. 54 Issue 7, p1014
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Treatment of chronic hepatitis C with interferon (IFN)-α and ribavirin has haematotoxic effects. We evaluated the effects of four different IFN/lFN-ribavirin treatment regimens on haematopoiesis. Methods: Haematopoiesis was studied in 133 patients with chronic hepatitis C receiving IFN-α2b alone (group A) or in combination with ribavirin (group B), pegylated IFN-α2a (group C), or pegylated IFN-α2b (group D) in combination with ribavirin. Results: At week 4, haemoglobin levels were diminished in all groups receiving combination therapy. In the monotherapy group, haemoglobin decreased slightly after eight weeks. In all groups, haemoglobin remained diminished throughout therapy. In all patients, leucocytes (while blood cells) decreased after four weeks and remained low during treatment. Platelets (peripheral platelet count (PPC)) were decreased in all groups after four weeks and remained below baseline levels during therapy in group A, C, and D whereas in group B PPC recovered early and reached baseline levels at week 16 of therapy. Concomitantly with the decreases in haemoglobin and PPC, erythropoietin increased in all groups receiving combination therapy and thrombopoietin in all groups. Patients treated with pegylated IFN-α2a and those who received pegylated IFN-α2b combination therapy differed only in leucopoiesis, whereas erythropoiesis and thrombopoiesis were comparable. Conclusion: IFN-α based therapies are associated with a decrease in all three haematopoietic lineages, irrespective of the type of therapy used. The stronger suppressive effect of pegylated IFN-α2a on leucopoiesis could be due to a dose effect. Overall, concentrations of endogenous haematopoietic growth factors are increased but can only partially alleviate haematotoxicity. Potential uses of exogenous haematopoietic growth factors and their impact on the virological response need to be explored.
ACCESSION #
17496274

 

Related Articles

  • POSSIBLE DIFFERENCES IN HEMATOLOGICAL ADVERSE EFFECTS IN MALES AND FEMALES DURING CHRONIC HEPATITIS C INFECTION THERAPY. Radović, Jelena; Jovanović, Branislav; Đorđević1, Jovana; Jevremović, Ljubica; Vujić, Stevan // Acta Medica Medianae;Jun2010, Vol. 49 Issue 2, p9 

    Chronic HCV infection therapy with pegylated-interferon plus ribavirin is associated with many adverse effects. The aim of our study was to determine the incidence of hematological adverse effects and their possible differences in males and females during chronic HCV infection therapy, as well...

  • Peginterferon-α-2b/ribavirin.  // Reactions Weekly;3/14/2009, Issue 1243, p37 

    The article describes the case of a 69-year-old woman who acquired immune thrombocytopenic purpura. The patient developed the said condition while undergoing treatment with peginterferon-α2b and ribavirin for chronic hepatitis C infection. She was administered with prednisolone to increase...

  • Erythropoietin Treatment Is Associated with More Severe Thrombocytopenia in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy. Homoncik, Monika; Sieghart, Wolfgang; Formann, Elisabeth; Schmid, Monika; Ferenci, Peter; Gangl, Alfred; Jilma, Bernd; Peck-Radosavljevic, Markus // American Journal of Gastroenterology;Oct2006, Vol. 101 Issue 10, p2275 

    BACKGROUND: Erythropoietin (EPO) not only stimulates erythropoiesis but also thrombopoiesis. As pegylated-interferon-α(PEG-IFN-α)-induced thrombocytopenia may become a limiting factor for continuation of therapy, the present study investigated if EPO can alleviate PEG-IFN-α induced...

  • Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. Kobayashi, Tomoe; Hige, Shuhei; Terashita, Katsumi; Nakai, Masato; Horimoto, Hiromasa; Sho, Takuya; Nakanishi, Mitsuru; Ogawa, Koji; Chuma, Makoto; Sakamoto, Naoya; Asaka, Masahiro // Journal of Gastroenterology;Nov2012, Vol. 47 Issue 11, p1228 

    Background: An inosine triphosphatase ( ITPA) single-nucleotide polymorphism (SNP) is associated with anemia induced by pegylated interferon and ribavirin (RBV) combination therapy in patients with chronic hepatitis C (CHC). However, there are very few reports on the hematological effects of RBV...

  • The markers predicting response to Hepatitis C virus treatment and evaluation of treatment responses. G�nal, �zg�r; Barut, H�seyin Sener; Erkorkmaz, �nal // Journal of Microbiology & Infectious Diseases;Sep2012, Vol. 2 Issue 3, p100 

    Objectives: Currently pegylated interferon alpha (peg-IFN) and ribavirin treatment is recommended for chronic hepatitis C treatment. The aim of treatment is to provide sustained viral response (SVR). Material and methods: A total of 125 patients, who have been treated for chronic hepatitis C...

  • Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. Nakagawa, Mina; Sakamoto, Naoya; Ueyama, Mayumi; Mogushi, Kaoru; Nagaie, Satoshi; Itsui, Yasuhiro; Azuma, Seishin; Kakinuma, Sei; Tanaka, Hiroshi; Enomoto, Nobuyuki; Watanabe, Mamoru // Journal of Gastroenterology;Jun2010, Vol. 45 Issue 6, p656 

    Pegylated-interferon-alpha 2b (PEG-IFN) plus ribavirin (RBV) therapy is currently the de-facto standard treatment for hepatitis C virus (HCV) infection. The aims of this study were to analyze the clinical and virological factors associated with a higher rate of response in patients with HCV...

  • Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study. Hiramatsu, Naoki; Inoue, Yuko; Oze, Tsugiko; Kurashige, Nao; Yakushijin, Takayuki; Mochizuki, Kiyoshi; Miyagi, Takuya; Tatsumi, Tomohide; Kiso, Shinichi; Kanto, Tatsuya; Kasahara, Akinori; Takehara, Tetsuo; Oshita, Masahide; Mita, Eiji; Hagiwara, Hideki; Inui, Yoshiaki; Katayama, Kazuhiro; Tamura, Shinji; Yoshihara, Harumasa; Imai, Yasuharu // Journal of Gastroenterology;Nov2011, Vol. 46 Issue 11, p1335 

    Background: The antiviral effect of pegylated interferon (Peg-IFN) plus ribavirin combination therapy in chronic hepatitis C (CHC) patients with normal alanine aminotransferase (ALT) levels (N-ALT) has been reported to be equivalent to that for patients with elevated ALT levels (E-ALT). However,...

  • Treatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid. Naz, Hasan; Aslan, Vahap // Journal of Infection in Developing Countries;2009, Vol. 3 Issue 8, p644 

    Pegylated interferon (PEG-IFN) alpha and ribavirin therapy has become the standard treatment in chronic hepatitis C virus (HCH)-infected patients. While thrombocytopenia associated with IFN use is frequently observed among these patients, autoimmune thrombocytopenia is one of the rarely observed...

  • Azathioprine/ribavirin interaction.  // Reactions Weekly;10/4/2008, Issue 1222, p8 

    The article describes the case of eight patients who all acquired severe pancytopenia. All patients developed their respective conditions while undergoing treatment with azathioprine for inflammatory bowel disease and ribavirin for hepatitis C. Two of the patients were found to have high levels...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics